Interface Biologics Extends Licensing Agreement with Fresenius Medical Care

Interface Biologics Inc. (IBI) announced that Fresenius Medical Care (FWB:FME, NYSE:FMS), the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
According to the press release:

n July 2010, IBI announced the signing of a definitive license and supply agreement whereby Fresenius Medical Care was offered an exclusive worldwide license to apply IBI’s EndexoTM technology to various components – including dialyzers and blood lines – of their chronic dialysis circuits for treating patients with end stage renal disease. This agreement has now been extended to include the acute dialysis market.
EndexoTM is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, thereby potentially reducing the use of drugs such as heparin. As an additive, Endexo™ has significant manufacturing advantages over other anti-thrombogenic coating or impregnation technologies and does not change the mechanical or functional properties of the underlying medical device.

Tom Reeves, President and CEO of Interface Biologics commented:

This extension of our licensing agreement with Fresenius Medical Care to include the acute dialysis market is further testament to the benefits of our Endexo surface modification technology.Acute dialysis is a critical therapy for many very ill patients and we believe that the Endexo additives will further improve the safety and effectiveness of these devices. The extension of our licensing agreement also underscores the continued progress that Fresenius has made in using the Endexo additives in their chronic dialysis circuits used in treating end stage renal disease.

Click here to view the full press release.